ePT--the Electronic Newsletter of Pharmaceutical Technology, Dec 27, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
ePT--the Electronic Newsletter of Pharmaceutical Technology, Dec 27, 2012
News
Amgen Settles False Claims Act Allegations
By Amy Ritter
Amgen has agreed to pay $762 million to resolve criminal liability and false claims act allegations.
FDA Issues Final Guidance on Limiting the Use of Certain Phthalates as Excipients
By Patricia Van Arnum
The agency recommends to avoid the use of to dibutyl phthalate and di(2-ethylhexyl) phthalate in CDER-regulated drug and biologic products, including prescription and nonprescription products.
FDA Approves First Anthrax Antitoxin
By Amy Ritter
Anthrax antitoxin is the first monoclonal antibody approved under FDA's Animal Efficacy Rule, and the first product from BARDA's Project Bioshield to receive FDA approval.
First Commercially-Available Mycoplasma Detection Test Accepted by FDA
By Adeline Siew, PhD
Roche's MycoTOOL, which offers rapid detection of mycoplasms based on a polymerase chain reaction (PCR) test, has received FDA acceptance.
University of Connecticut Studies Drug-Carrying Nanoparticles
By Jennifer Markarian
A University of Connecticut chemical engineering professor received a National Science Foundation grant to study how nanoparticles flow in the bloodstream, which is crucial for their use in drug delivery.
Week of December 24, 2012: AAIPharma Expands Parenteral Drug Capacity; Novartis Buys Dendreon Plant; and More
AAIPharma Expands Parenteral Drug Capacity; Novartis Buys Dendreon Plant; and More.

ADVERTISEMENT
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
21%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FindPharma Custom Search
Featured Jobs

More Jobs
Click here